Here are four things to know.
1. The study aims to compare the efficacy of ESG and lifestyle modification to lifestyle modification alone in resolving NASH without worsening of fibrosis in obese patients. The study intends to improve liver histology in obese NASH patients without increased bariatric surgery risks.
2. Nearly 82 percent of NASH patients are obese. NASH results from triglyceride accumulation in the liver, causing inflammation which can lead to cirrhosis. Nearly 82 percent of NASH patients are obese, and NASH affects over 5 percent of the global population.
3. The OverStitch Endoscopic Suturing System allows physicians to place full-thickness sutures from a flexible endoscope.
4. Apollo Endosurgery is a bariatric and gastrointestinal medical device company with products offered in more than 70 countries.
Here is more information on the trial.
More articles on gastroenterology:
5 most read GI stories May 7-11
4 takeaways from Exact Sciences CEO Kevin Conroy on the company’s past, present & future
Exelixis’ and Roche’s combined colon cancer therapy failed — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.